Does treatment with Non-Vitamin-K Oral Anticoagulants (NOACs) affect the combined rate of ischemic embolic recurrence and severe bleeding in patients with acute ischemic stroke and atrial fibrillation?
In patients with acute ischemic stroke and atrial fibrillation, NOAC therapy is associated with a 5% combined rate of recurrent ischemia and severe bleeding at 90 days.
In patients with acute ischemic stroke and atrial fibrillation, treatment with NOACs was associated with a combined 5% rate of ischemic embolic recurrence and severe bleeding within 90 days.
Paciaroni et al. (Thu,) studied this question.